443 Frequency of IL-22 expression on CD4+ T cells in psoriatic lesion may negatively correlate with the disease prognosis

Interleukin (IL)-22, together with IL-23 and IL-17, is up-regulated in psoriatic lesions has been suggested to be involved the pathogenesis of psoriasis. However, while IL-17 have established as valid therapeutic targets psoriasis, anti-IL-22 antibody failed show its efficacy clinical trial for psoriasis vulgaris. Since it reported that better effect was achieved anti-TNFα antibodies arthritis (PsA) subjects high serum IL-22 levels, anti-IL-17A were suited those low possible expression reflects specific subpopulations Here, we analyzed association between disease prognosis frequency IL-22-positive CD4+ T cells skin 17 patients who had not received systemic treatments. According percentages among dermal on paraffin-embedded immune-stained sections, defined Th22 score 0 (< 20%), 1 (20-60%), or 2 (> 60%) (score 0, 1, 2: n = 6, 9, 2, respectively). No predominant correlation found duration, age, recent topical treatment. Although no PASI (5.83 ± 4.04 4.93 4.50 4.70 0.57 2), scores showed incidence PsA (50.0 % 22.2 2). In addition, subsequent introduction biologics one year frequent (60.0 11.1 Our study implies higher lesional CD4+T may act a suppressive manner against progression.